+ Watch OXBT
on My Watchlist
The product of theirs to watch is Oxycyte. Half way through phase 2b trials in EU and Israel. This stuff is a game changer for those with traumatic brain injury and stroke.
These tests will have no effect on your grades. They merely determine your future social status and financial success.
After years of futility attempting to develop their synthetic oxygen-carrying compound Oxycyte, Oxygen has finally successfully commercialized a product. It's called preferred stock, and they've been selling tons of it lately. Their follow-on product, warrants, has also been doing well. Of course, selling those products doesn't do wonders for the share count or the stock price but there's a cure for that too - a reverse split. Now the stock is at 1.5 again and there's just a couple million shares with no one the wiser, except the old shareholders who have a twentieth of the shares that they had the last time the stock was at 1.5.It will be interesting to see which way Oxygen chooses to go at this point. One choice would be the old low-float pop on some manufactured catalyst or phony sellside buy rating. I remember Rosetta Genomics had some fun with that one not too long ago. I'm just happy to get Oxygen back into CAPS, as I had thought them lost forever after their last disappearance below the 50 cent threshold. Thank god for reverse splits.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions